Department of Hematology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, China.
Department of Ophthalmology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, China.
Ocul Immunol Inflamm. 2022 Aug;30(6):1541-1543. doi: 10.1080/09273948.2021.1900876. Epub 2021 Mar 18.
Among severely immunosuppressed patients resistant or refractory cytomegalovirus (CMV) retinitis is not uncommon, and is potentially blinding in the affected eye. Immunotherapy using CMV-specific cytotoxic T lymphocytes (CTLs) is an emerging and promising alternative for the control of resistant or refractory CMV retinitis. However, highly purified CMV-CTLs are still not available in the majority of medical institutions in China because the generation of CMV-CTLs is labor intensive, time-consuming and expensive.
This letter describes the clinical responses to a simplified CMV-CTL immunotherapy aimed at controlling drug-resistant CMV retinitis in two immunodeficient patients.
Our cases suggest that the simplified CMV-CTL immunotherapy offers a highly efficient and low-cost solution to drug-resistant CMV retinitis. This immunotherapy strategy targeting drug-resistant CMV retinitis is likely to be cost-effective in the context of a specific patient population.
在严重免疫抑制的患者中，出现对抗病毒药物耐药或难治性巨细胞病毒（CMV）视网膜炎并不罕见，而且可能会导致受影响的眼睛失明。使用 CMV 特异性细胞毒性 T 淋巴细胞（CTL）的免疫疗法是一种新兴的、有前途的方法，可以控制耐药或难治性 CMV 视网膜炎。然而，由于 CMV-CTL 的产生劳动强度大、耗时且昂贵，因此在中国的大多数医疗机构中仍然无法获得高度纯化的 CMV-CTL。
本信函描述了针对两名免疫缺陷患者的耐药性 CMV 视网膜炎，采用简化的 CMV-CTL 免疫疗法的临床反应。
我们的病例表明，简化的 CMV-CTL 免疫疗法为耐药性 CMV 视网膜炎提供了一种高效且低成本的解决方案。针对耐药性 CMV 视网膜炎的这种免疫治疗策略，在特定的患者人群中可能具有成本效益。
